נק' מוניטין:
58,705
- 103,265
- 12,428
👹Diabetes Obes Metab. 2010 Nov 18. doi: 10.1111/j.1463-1326.2010.01332.x. [Epub ahead of print]
Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial.
Mooren FC, Krüger K, Völker K, Golf SW, Wadepuhl M, Kraus A.
Department of Sports Medicine, Institute of Sports Sciences, Justus-Liebig-University, Kugelberg 62, Giessen 35394, Germany Department of Sports Medicine, Münster-University Hospital, Münster 48129, Germany Department of Laboratory Medicine, Justus-Liebig-University, Giessen 35394, Germany VSA Versuchsplanung und statistische Auswertung, Ulm 89077, Germany Verla-Pharm Arzneimittel, Hauptstraße 98, Tutzing 82324, Germany.
Abstract
The incidence of insulin resistance and metabolic syndrome correlates with the availability of magnesium (Mg). We studied the effect of oral Mg supplementation on insulin sensitivity and other characteristics of the metabolic syndrome in normomagnesemic, overweight, insulin resistant, non-diabetic subjects. Subjects were tested for eligibility using oral glucose tolerance test und subsequently randomized to receive either magnesium-aspartate-hydrochloride (n = 27) or placebo (n = 25) for 6 months. As trial endpoints several indices of insulin sensitivity, plasma glucose, serum insulin, blood pressure and lipid profile were determined. Mg supplementation resulted in a significant improvement of fasting plasma glucose and some ISI compared to placebo. Blood pressure and lipid profile didn't show significant changes. The results provide significant evidence that oral Mg supplementation improves insulin sensitivity even in normomagnesemic, overweight, non-diabetic subjects emphasizing the need for an early optimisation of Mg status to prevent insulin resistance and subsequently type 2 diabetes.
© 2010 Blackwell Publishing Ltd.
PMID: 21205110 [PubMed - as supplied by publisher]